Cargando…
MicroRNA and metabolomics signatures for adrenomyeloneuropathy disease severity
Adrenomyeloneuropathy (AMN), the slow progressive phenotype of adrenoleukodystrophy (ALD), has no clinical plasma biomarker for disease progression. This feasibility study aimed to determine whether metabolomics and micro‐RNA in blood plasma provide a potential source of biomarkers for AMN disease s...
Autores principales: | Turk, Bela Rui, Poisson, Laila Marie, Nemeth, Christina Linnea, Goodman, Jordan, Moser, Ann B., Jones, Richard Owen, Fatemi, Ali, Singh, Jaspreet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626672/ https://www.ncbi.nlm.nih.gov/pubmed/36341174 http://dx.doi.org/10.1002/jmd2.12323 |
Ejemplares similares
-
Adrenomyeloneuropathy.
por: Dickey, W., et al.
Publicado: (1987) -
Adrenomyeloneuropathy Presenting With Adrenal Insufficiency
por: Park, Hee Dong, et al.
Publicado: (2013) -
Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study
por: Casasnovas, Carlos, et al.
Publicado: (2019) -
Adrenomyeloneuropathy with bulbar palsy: A rare association
por: Chafale, Vishal Annaji, et al.
Publicado: (2014) -
Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy
por: Jønch, Aia Elise, et al.
Publicado: (2012)